A Phase I/II Study of Neratinib in Pediatric Patients With Relapsed or Refractory Solid Tumors
Latest Information Update: 16 Apr 2024
At a glance
- Drugs Neratinib (Primary)
- Indications CNS cancer; Haematological malignancies; Leukaemia; Solid tumours
- Focus Adverse reactions
- 09 Apr 2024 Status changed from recruiting to active, no longer recruiting.
- 21 Mar 2022 Planned End Date changed from 1 Oct 2023 to 1 Oct 2024.
- 21 Mar 2022 Planned primary completion date changed from 1 Oct 2023 to 1 Oct 2024.